

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 76852

Title: Would a gemcitabine plus nab-paclitaxel work better in the treatment of metastatic pancreatic cancer if combined with a new targeted agent? a meta-analysis

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05048160

Position: Peer Reviewer

Academic degree: PhD

Professional title: Professor

Reviewer's Country/Territory: Italy

Author's Country/Territory: China

Manuscript submission date: 2022-04-03

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-04-04 07:08

Reviewer performed review: 2022-04-20 01:18

Review time: 15 Days and 18 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

Peer-reviewer statements	Peer-Review: [<input checked="" type="radio"/>] Anonymous [<input type="radio"/>] Onymous
	Conflicts-of-Interest: [<input type="radio"/>] Yes [<input checked="" type="radio"/>] No

SPECIFIC COMMENTS TO AUTHORS

Concerning manuscript no. 76852 by li et al. titled "Would a gemcitabine plus nab-paclitaxel work better in the treatment of metastatic pancreatic cancer if combined with a new targeted agent? a meta-analysis"- this is an important review together with a meta analysis that permits the reader to undersyand whether the combination of targeted therapies with the clinically utilized gemcitabine/ nab-paclitaxel combination which the authors call "GA" will improve patient response. It is an important, well written and well thought-out manuscript that suggests that it will be necessary to discover novel targeted therapies in the future to improve PDAC therapy. There is only a small problem on page 5 of the manuscript received by me in which, probably due to typographical errors, it is not clear what the authors wanted to say- here following I have put question marks in red in the parts that are not clear: "In an Ib study evaluating the safety and tolerability ofPEGPH 20 in combination with GEM, ???the results showed ??? In an Ib study evaluating the safety and tolerability of PEGPH 20 in combination with GEM for advanced pancreatic cancer. ???S indicated by the results, PEGPH 20 was well tolerated, especially in patients with high HA [12]. " After the correction of the above cited problem, I highly recommend this manuscript for immediate publication.

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 76852

Title: Would a gemcitabine plus nab-paclitaxel work better in the treatment of metastatic pancreatic cancer if combined with a new targeted agent? a meta-analysis

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 04721358

Position: Peer Reviewer

Academic degree: MD

Professional title: Associate Professor

Reviewer's Country/Territory: Italy

Author's Country/Territory: China

Manuscript submission date: 2022-04-03

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-04-26 05:35

Reviewer performed review: 2022-05-02 12:03

Review time: 6 Days and 6 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

Peer-reviewer statements	Peer-Review: [<input checked="" type="radio"/>] Anonymous [<input type="radio"/>] Onymous Conflicts-of-Interest: [<input type="radio"/>] Yes [<input checked="" type="radio"/>] No
-------------------------------------	---

SPECIFIC COMMENTS TO AUTHORS

In their manuscript, Li et al. reviewed the role of gemcitabine plus nab-paclitaxel combined with new targeted drugs in the treatment of metastatic pancreatic cancer. After inclusion of 7 RCTs in a meta-analysis for a total of 1544 patients, the Authors concluded that the addition of novel targeted agents did not result in a survival advantage for patients with advanced pancreatic cancer. This is an interesting topic, it is a comprehensive review, and the paper is well-written. There are only typos to correct and I recommend publication.